Toronto  – Eli Lilly Canada announced approval of Trulicity (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes to improve glycemic control. GLP-1 is a naturally occurring intestinal hormone that is released when people eat, causing reduced appetite and the release of insulin.1 Trulicity is delivered in a pre-filled, single-use pen with …